eVetPractice vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 53)
eVetPractice logo

eVetPractice

ChallengerHealthtech

Veterinary Practice Management

Cloud veterinary practice management covering records, scheduling, invoicing, and pharmacy for small-animal clinics. El Segundo CA; developed by Covetrus as the cloud-native complement to legacy AVImark;

AI VisibilityBeta
Overall Score
C53
Category Rank
#235 of 596
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
58
Gemini
56

About

eVetPractice is an El Segundo, California-based cloud-based veterinary practice management software that provides independent veterinary clinics with scheduling, electronic medical records, treatment tracking, invoicing, pharmacy management, and client communication in a single web-based platform. Developed by Covetrus, eVetPractice represents the company's cloud-native veterinary practice management offering alongside its legacy AVImark on-premise system, targeting practices ready to move to a browser-based system without the hardware and IT maintenance overhead of on-premise software. The platform is designed for small-animal general practices and emergency hospitals, with clinical templates and workflows appropriate for companion animal medicine.\n\neVetPractice's pharmacy management module is a notable capability, allowing veterinary practices to manage in-clinic medication dispensing, track controlled substance logs, and connect to online pharmacy fulfillment through Covetrus's online pharmacy network. This pharmaceutical connectivity aligns with Covetrus's broader strategy of integrating its animal health distribution and pharmacy businesses with its practice management software. Practices using eVetPractice can process prescription refill requests and manage client prescription histories within the same system used for scheduling and medical records, reducing the context-switching that comes with managing separate pharmacy and practice management platforms.\n\neVetPractice competes with Shepherd, Digitail, ezyVet, and the modernized versions of legacy systems in the cloud veterinary practice management market. The company's positioning within Covetrus gives it integration advantages with the broader Covetrus ecosystem including diagnostic imaging, laboratory connectivity, and prescription management, but also means its development roadmap is influenced by the priorities of a large animal health distributor rather than solely by independent veterinary practice needs. eVetPractice serves practices primarily in the United States with a focus on the independent practice segment.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

53
Overall Score
81
#235
Category Rank
#17
82
AI Consensus
71
stable
Trend
stable
52
ChatGPT
80
58
Perplexity
75
56
Gemini
77
51
Claude
86
55
Grok
85

Key Details

Category
Veterinary Practice Management
General
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only eVetPractice
Veterinary Practice Management

Integrations

Only eVetPractice
Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.